Health

GC Biopharma/Novel Pharma's Sanfilippo Syndrome Treatment Obtains FDA IND Clearance

YONGIN, South Korea, May 21, 2024 /PRNewswire/ -- GC Biopharma (006280. KS) and Novel Pharma have announced that the U.S. FDA has cleared the investigational new drug (IND) application for their jointly developed MPSIIIA (Sanfilippo Syndrome Type A) treatment, GC1130A. With this FDA clearance,...

2024-05-21 15:12 1418

Dr. Philip Fan J.P. (范榮彰博士) Opens One-Stop Dental Facility in Shenzhen to Cater to New Consumption Patterns of Hong Kong Residents

HONG KONG, May 21, 2024 /PRNewswire/ -- The lifting of pandemic travel restrictions has driven a surge of Hong Kongers visiting mainlandChina for consumption, with dental services becoming a popular spending category. The dental clinic opened inShenzhen by Dr. Philip Fan, J.P. (范榮彰博士), the former...

2024-05-21 14:37 16531

ZYMFENTRA™ (infliximab-dyyb) demonstrated long-term efficacy and safety profile of maintenance treatment through two years for adults with moderately to severely active Crohn's disease and ulcerative colitis

* Findings from the extended LIBERTY studies and associated post-hoc analysis support the long-term efficacy and safety of ZYMFENTRA™, the first and only FDA-approved subcutaneous infliximab[1],[2] * Data from a post-hoc analysis of the LIBERTY-CD study showed that, despite affecting drug lev...

2024-05-21 12:01 1697

Proto Axiom Launches The Challenger Summit: Australia's Premier Biotech Pitch-Event with over $250,000 in Grant Financing

SYDNEY, May 21, 2024 /PRNewswire/ -- Proto Axiom, Australia's first true biotech incubator, is thrilled to announce the launch of The Challenger Summit. The Challenger Summit will provide a unique platform for researchers to showcase their innovative biotech solutions, competing for over$250,000 ...

2024-05-21 11:28 1860

ILJIN SNT Co., Ltd. Calls for Board Restructure at Aurinia Pharmaceuticals

SEOUL, South Korea, May 21, 2024 /PRNewswire/ -- Fellow Aurinia Shareholders, ILJIN SNT Co., Ltd. and its affiliates (collectively, "ILJIN") is a long-term holder of more than 5% of Aurinia Pharmaceuticals Inc. ("Aurinia" or the " Company") and has been supportive of the Company's mission since 2...

2024-05-21 09:49 1490

Innovent Announces the New Drug Application of IBI311 (IGF-1R antibody) has been Accepted by the NMPA of China for Thyroid Eye Disease

SAN FRANCISCO and SUZHOU, China, May 21, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune, ophthalmology and ot...

2024-05-21 08:55 2300

USANA Provides Sustainable Nutrition to Malapascua Island Through Garden Tower Project

100 Garden Towers planted on the island MANILA, Philippines, May 21, 2024 /PRNewswire/ -- The USANA Foundation, the philanthropic arm of USANA Health Sciences—along with 30 USANA distributors from seven countries—recently built 100 Garden Towers on the island of Malapascua, Cebu, in pursuit of p...

2024-05-21 08:28 2086

Telix Completes Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate Cancer

* CUPID is a Phase I safety and dosimetry study of TLX592, Telix's investigational antibody-based targeted alpha therapy for prostate cancer. * Establishes proof-of-concept for Telix's proprietary RADmAb® engineered antibody platform, currently under pre-clinical evaluation for multiple cancer...

2024-05-21 07:58 1511

Pierre Fabre Laboratories announces the submission by Atara Biotherapeutics of Tabelecleucel (Tab-cel®) Biologics License Application for treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S FDA

* First Allogeneic T-Cell Therapy BLA Submission to U.S. Food and Drug Administration  * The BLA is supported by data from the pivotal Phase 3 ALLELE study which was investigating Tab-cel in relapsed or refractory EBV+ PTLD following solid organ transplant (SOT) or hematopoietic cell transpla...

2024-05-20 21:30 2045

Lunit Achieves Historic Milestone: 100 Peer-Reviewed Papers Published on Its AI Medical Imaging Suite

- From research to real-world impact: Lunit demonstrates Lunit INSIGHT's clinical safety, effectiveness, and efficiency in 100 papers SEOUL, South Korea, May 20, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today ...

2024-05-20 21:00 2002

Duoning Collaborates with Bioelectronica to Commercialize a Single-Cell Sorting System for Antibody Discovery

SHANGHAI, May 20, 2024 /PRNewswire/ -- Duoning Biotechnology Group ("Duoning"), a leading one-stop bioprocess provider inChina, today announced a strategic partnership with Bioelectronica, a company focusing on developing tools for single-cell/single-bacteria research. This partnership aims to en...

2024-05-20 20:00 1785

HaemaLogiX welcomes former Australian Federal Minister for Health Professor the Hon Greg Hunt to the company board as Non-Executive Director

SYDNEY, May 20, 2024 /PRNewswire/ -- HaemaLogiX Ltd, a clinical stage biotech developing novel immunotherapies for patients with blood cancers and B-cell diseases, is pleased to announce the appointment of Professor the Hon Greg Hunt, former Australian Federal Minister for Health, to the HaemaLog...

2024-05-20 18:00 1654

TREEFROG PRESENTS DATA FROM THEIR PARKINSON'S DISEASE CELL THERAPY PROGRAM AT THE 29TH WORLD CONGRESS ON PARKINSON'S DISEASE AND RELATED DISORDERS (IAPRD) IN LISBON

BORDEAUX, France, May 20, 2024 /PRNewswire/ -- TreeFrog Therapeutics will participate for the first time at the IAPRD, to present data from their Parkinson's disease cell therapy program, which has demonstrated excellent results with full motor recovery at 16 weeks in preclinical studies.[1] Par...

2024-05-20 14:30 1670

GC Biopharma/Novel Pharma's Sanfilippo Syndrome Treatment Obtains FDA IND Approval

YONGIN, South Korea, May 20, 2024 /PRNewswire/ -- GC Biopharma (006280. KS) and Novel Pharma announced that its jointly developed MPS IIIA 'GC1130A' treatment has received FDA IND approval. With this approval, development of 'GC1130A' is expected to accelerate with multinational clinical trial...

2024-05-20 14:07 1456

Subang Jaya Medical Centre Applauded by Frost & Sullivan as the Best Hospital Company of the Year in Malaysia for the fourth consecutive year

SJMC's significant efforts in alleviating nursing shortages, enhancing workflows and its strong market-leading position, both locally and globally resulted in high patient retention and strong referrals. SAN ANTONIO, May 20, 2024 /PRNewswire/ -- Frost & Sullivan recently analyzed the hospital in...

2024-05-20 10:00 1767

Hong Kong Breast Cancer Foundation Symposium on Breast Health Education 2024

Latest Breast Cancer Diagnosis and Treatment, Integrating Traditional Chinese Medicine and Mind-Body-Spirit Healing HONG KONG, May 20, 2024 /PRNewswire/ -- Breast cancer is the most common cancer among women inHong Kong, and the third leading cause of cancer-related deaths; affecting numerous fa...

2024-05-20 08:33 1511

Innovent Announces Oral Presentations at ESMO Plenary and ESMO GI Congress on Clinical Data of IBI363 (PD-1/IL-2) and IBI343 (CLDN18.2 ADC)

SAN FRANCISCO and SUZHOU, China, May 19, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune,...

2024-05-20 08:20 2270

Orion Health awarded Panda Health Partner status for its Orchestral Health Intelligence Platform

NEW YORK, May 19, 2024 /PRNewswire/ -- Orion Health , a global leader in digital health solutions, announced today that it has been awarded partner status byPanda Health for its Orchestral

2024-05-19 23:10 1811

More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024

Grace Sun, 16, receives $75,000 Top Award for a new kind of organic electrochemical transistor at the world's largest pre-college science, technology, engineering and math (STEM) competition. TARRYTOWN, N.Y. and WASHINGTON, May 18, 2024 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: RE...

2024-05-18 05:46 3350

HOYA Group Company, PENTAX of America, Inc. and MAGENTIQ EYE Ltd. Announce their Intention to Form a Distribution Partnership for the U.S Market

WASHINGTON D.C., May 17, 2024 /PRNewswire/ -- HOYA Group Company, PENTAX of America, Inc. (PENTAX Medical) and MAGENTIQ-EYE Ltd., an AI medical device company, announced today their intention to form a partnership in the field of AI in Gastroenterology and to examine further collaboration and str...

2024-05-17 22:00 5441
1 ... 83848586878889 ... 858